From: Cost drivers in the pharmacological treatment of interstitial lung disease
IPF | PF-ILD | Sarcoidosis | Other ILD | |
---|---|---|---|---|
OR [95% CI] | OR [95% CI] | OR [95% CI] | OR [95% CI] | |
Male | 1.03 [0.65–1.41] | 1.73 [1.27–2.20]* | 2.56 [1.58–3.54]* | 1.02 [0.64–1.40] |
Former/current smoker | 1.25 [0.92–1.59] | 0.57 [0.13–1.00] | 2.62 [1.79–3.46]* | 1.00 [0.59–1.41] |
Age | 0.99 [0.97–1.01] | 1.05 [1.03–1.07]* | 1.03 [0.99–1.07] | 0.99 [0.97–1.01] |
FVC % pred. At baseline | 1.00 [0.99–1.00] | 1.00 [0.99–1.01] | 1.00 [0.97–1.03] | 0.99 [0.98–1.00] |
Disease duration | 1.11 [1.03–1.19]* | 0.92 [0.88–0.96]* | 0.94 [0.89–0.99]* | 0.93 [0.89–0.97]* |
Comorbidity sum score | 1.04 [0.96–1.13] | 1.52 [1.31–1.74]* | 1.60 [1.23–1.97]* | 1.24 [1.11–1.38]* |
T1 | 1.24 [0.87–1.61] | 2.22 [1.72–2.71]* | 0.77 [0.42–1.12] | 1.05 [0.67–1.42] |
T2 | 5.95 [5.59–6.30]* | 11.8 [11.3–12.3]* | 2.09 [1.64–2.54]* | 6.46 [6.05–6.86]* |